Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 304

Results For "RAT"

8017 News Found

Roche’s PiaSky approved in the EU for treatment of people with PNH
Drug Approval | September 03, 2024

Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration


Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain
People | September 03, 2024

Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain

Birajeev is a seasoned Supply Chain leader with an experience of 23 years


Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Clinical Trials | September 03, 2024

Tolebrutinib meets primary endpoint in HERCULES phase 3 study

Phase 3 study results will form the basis for future discussions with global regulatory authorities


Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure
Clinical Trials | September 02, 2024

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%


Govt. to improve availability of infrastructure and trained manpower for organ transplantation
News | September 01, 2024

Govt. to improve availability of infrastructure and trained manpower for organ transplantation

Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country


Biocon Pharma receives USFDA approval for daptomycin
Drug Approval | September 01, 2024

Biocon Pharma receives USFDA approval for daptomycin

The approval further adds to Biocon’s portfolio of complex drug products


Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
News | August 31, 2024

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025